Therapeutic compositions that alter the immune response

Details Therapeutic compositions that alter the immune response Therapeutic compositions that alter the immune response

1999-08-18

2008-01-15

Canella, Karen A. (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S133100, C424S134100, C424S135100, C424S138100, C424S141100, C424S178100

Reexamination Certificate

active

07318921

ABSTRACT:
The invention is therapeutic methods and compositions that alter the immunogenicity of the host.

REFERENCES:
patent: 3865689 (1975-02-01), Goldenberg
patent: 4331647 (1982-05-01), Goldenberg
patent: 4740371 (1988-04-01), St. Remy et al.
patent: 4879225 (1989-11-01), Morgan, Jr. et al.
patent: 5053224 (1991-10-01), Koprowski et al.
patent: 5165922 (1992-11-01), Hellstrom et al.
patent: 5512283 (1996-04-01), Byers et al.
patent: 5532159 (1996-07-01), Webb et al.
patent: 5583202 (1996-12-01), Zanetti
patent: 5591593 (1997-01-01), Courtenay-Luck
patent: 5652114 (1997-07-01), Chu et al.
patent: 5688657 (1997-11-01), Tsang et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5977315 (1999-11-01), Chatterjee et al.
patent: 6068830 (2000-05-01), Diamandis et al.
patent: 6077519 (2000-06-01), Storkus et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6140091 (2000-10-01), Raso et al.
patent: 6241985 (2001-06-01), Madiyalakan et al.
patent: 0 234 122 (1987-09-01), None
patent: 0 308 208 (1989-03-01), None
patent: WO 87/00053 (1987-01-01), None
patent: WO 88/03954 (1988-06-01), None
patent: WO 89/05140 (1989-06-01), None
patent: WO95/04548 (1995-02-01), None
patent: WO98/57661 (1998-12-01), None
Madiyalakan et al (Hybridoma, Apr. 1995, vol. 14(2):199-203.
Baum et al (Hybridoma, 1993, vol. 12(5):583-9.
Baum et al (Cancer Supplement, 1994, vol. 73(3):1121-1125).
Baum et al. (Hybridoma, vol. 12, No. 5, 1993, pp. 583-589).
Madiyalakan et al. (Hybridoma, vol. 14, No. 2, May 19, 1995).
Ward et al., “Unconjugated antibodies for cancer therapy: lessons from the clinic”, Cancer Treatment Reviews, 1997, vol. 23, pp. 305-319.
Leitzel et al. Elevated Soluble c-erbB-2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients, Jnl.Clin.Oncol., 1992, vol. 10. No. 9, pp. 1436-1443.
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, p. 1).
Kedar and Klein (‘Cancer Immunotherapy’ In: Advances in Cancer Research, 1992, vol. 59, pp. 245-323.
Schultze et al (Trends in Immunology, 2004, vol. 25, pp. 659-664).
Bodey et al, (Anticancer Research, 2000, vol. 20, pp. 2665-2676).
Abstract of Semino et al (Journal of Biological Regulators and Homeostatic Agents, 1993, vol. 7, pp. 99-105).
Abstract of Algarra et al, International Journal of Clinical and Laboratory Research, 1997, vol. 27, pp. 95-102.
Paul, Fundamental Immunology, (text), 1993.
Ohlen et al (Journal of Immunology, 2001, vol. 166, pp. 2863-2870.
Lee et al, Journal of Immunology, 1999, vol. 163, pp. 6292-6300.
Benichou et al, 1994, vol. 6, pp. 131-138.
Abstract of Pani et al (Immunological Investigations, 1994, vol. 23, pp. 337-346.
Sotomayor et al, Critical Reviews in Oncogenesis, 1996, vol. 7, pp. 433-456.
Nishimura et al, Cancer Chemother Pharmacol, 2000, vol. 46, suppl. pp. S52-S61.
PCT International Search Report Corresponding To PCT International Application No. PCT/IB99/01114; Authorized Officer: M. Covone; Date of Completion: Nov. 30, 1999; Date of Mailing: Dec. 15, 1999 (8 pages).
Madiyalakan, R. et al., HYBRIDOMA, vol. 14, No. 2, 1995, “Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA 125 Murine Monoclonal Antibody B43.13”, pp. 199-203.
Leveugle, B. et al., Proceedings of the American Associate for Cancer Research Annual Meeting, vol. 39, Mar. 1998, “PSA-directed immunotherapy of prostate cancer.”, p. 355, (1 page).
Chattopadhyay et al., “Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1,” Cancer Res., 5:6045-51 (1991).
Clark, Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), Prot. Eng., 1 (1993).
Crowley et al., “Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins”, J. Exp. Med., 172:383-386 (1990).
De la Salle, “FcγR on Human Dendritic Cells”, Human IgG Receptors, p. 39-55 (1996).
Fagerberg, “Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A,” Cancer Imm., 12:81-87 (1996).
Frodin et al., Hybridoma, “Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome—an important antitumoral effector funtion?,” 10:421-31 (1991).
Goldenberg et al., “Cancer Diagnosis and Therapy with Radiolabeled Antibodies”, In: Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, Vogel. Ed., 259-280 (1987).
Keder et al., “Cancer Immunotherapy: Are the results discouraging? Can they be improved?”, Adv. Cancer Res., 59:245-323 (1992).
Abbas AK et al., “Antigen presentation by B lymphocytes,”Antigen Presenting Cells: Diversity, Differentiation, and Regulation269-279 (1988).
Adams S et al., “Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings,”Eur J Nucl Med.25(9):1277-83 (1998).
Alzona M et al., “IL-12 activates IFN-gamma production through the preferential activation of CD30+ T cells,”J Immunol.154(1):9-16 (1995).
American Cancer Society, “Cancer Facts and Figures,” Atlanta, GA: American Cancer Society (1995).
Andersson K et al., “Modulation of antigen-antibody complexations by immunoglobulins,”Scand J Immunol.42(4):407-17 (1995).
Bachmann MF et al., “Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen,”Eur J Immunol.24(10):2567-70 (1994).
Barnd DL et al., “Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells,”Proc Natl Acad Sci U S A.86(18):7159-63 (1989).
Bartoloni C et al., “Assay, isolation and characterization of circulating immune complexes from serum of gastrointestinal cancer, stage III and IV melanoma and chronic inflammatory bowel disease patients,”Oncology50(1):27-34 (1993).
Bast RC Jr. et al., “A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer,”New England J. Med.309(15):883-7 (1983).
Baum RP et al., “Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma,”Cancer73(3 Suppl):1121-5 (1994).
Bernard NF et al., “Possible Role for Specific Surface Immunoglobulin In Antigen Presentation,”Antigen Presenting Cells: Diversity, Differentiation, and Regulation291-300 (1988).
Boon T et al., “Tumor antigens recognized by T lymphocytes,”Annu Rev Immunol.12:337-65 (1994).
Brakenhoff RH et al., “Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer,”Cancer Immunol Immunother.40(3):191-200 (1995).
Bretscher PA et al., “Establishment of stable, cell-mediated immunity that makes “susceptible”mice resistant to Leishmania major,”Science257(5069):539-42 (1992).
Brockmeyer NH et al., “Immunomodulation of cimetidine in healthy volunteers,”Klin Wochenschr.67(1):26-30 (1989).
Bouige P et al., “Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes,”Hybridoma9(6):519-26 (1990).
Bukowski RM et al., “Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies,”J Immunother.10(6):432-9 (1991).
Canevari S et al., “Regression of advanced ovarian carcinoma by intraperitoneal treatment with auto

Affiliated with

Also associated with

Rating

Therapeutic compositions that alter the immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic compositions that alter the immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions that alter the immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3964881